Changes in serum levels of cytokeratin-18 fragments in patients with chronic hepatitis C under antiviral therapy
- 24 April 2018
- journal article
- Published by Turkish Journal of Academic Gastroenterology in Akademik Gastroenteroloji Dergisi
- Vol. 17 (1) , 28-32
Abstract
Background and Aims: Cytokeratin-18 is the known substrate for caspases, which are encountered during hepatic and pancreatic acinar apoptosis. Studies performed in recent years have indicated that the cleavage level of serum cytokeratin-18 (M30 antigen) is correlated with hepatic fibrosis and disease severity in both chronic hepatitis C and non-alcoholic steatohepatitis. It was shown that antiviral therapy in chronic viral hepatitis C patients significantly reduced hepatocellular apoptosis and cytokeratin-18 is accepted as a reliable marker of hepatocyte apoptosis. Our aim was to determine the correlation between the cytokeratin-18 level and treatment response in patients with chronic viral hepatitis C. Materials and Methods: Sixty patients with chronic viral hepatitis C were included in the study. A 48-week course of peginterferon- ribavirin therapy was given to appropriate patients. Hepatitis C virus RNA was measured at 0, 12, and 24 weeks at the end of therapy and 72 weeks. In addition, cytokeratin-18 levels were measured at 0, 24, and 72 weeks. Results: The mean age of 60 patients was 52±10.9 years. While 31 (51.6%) of patients were in the sustained viral response group, 29 (8.4%) of patients were in the non-sustained viral response group. It was determined that while the cytokeratin-18 level at week 0 in the sustained viral response group was 243±21, the cytokeratin-18 level at week 24 was 115±12 U/L and the difference between the level of cytokeratin-18 at weeks 0 and 24 were 127±209 U/L (p: .014). While the cytokeratin-18 level at week 0 in the non- sustained viral response group was 270±14; at week 24, the cytokeratin-18 level was 136±19 U/L and the difference between cytokeratin-18 levels at weeks 0 and 24 was 136±156 U/L (p > .5). At week 72, the cytokeratin-18 level in the sustained viral response group was 109±38 and the difference between weeks 0 and 72 was 134±215 (p < .002). Conclusion: In chronic viral hepatitis C patients, there was a correlation between sustained viral response and cytokeratin-18, which is a marker of apoptosis. During treatment, it was found that there was a relationship between sustained viral response and the decrease in cytokeratin-18 levels. Thisfinding indicates that cytokeratin-18 level monitoring may be used as a predictive marker of sustained viral response.Keywords
This publication has 15 references indexed in Scilit:
- Significance of Serum Cytokeratin-18 in Prediction of Hepatocellular Carcinoma in Chronic Hepatitis C Infected Egyptian PatientsOpen Access Macedonian Journal of Medical Sciences, 2015
- Serum cytochrome c and m30‐neoepitope of cytokeratin‐18 in chronic hepatitis CLiver International, 2013
- KeratinsCurrent Opinion in Gastroenterology, 2012
- Effect of antiviral therapy on circulating cytokeratin-18 fragments in patients with chronic hepatitis CJournal of Viral Hepatitis, 2010
- Elevated apoptosis-associated cytokeratin 18 fragments (CK18Asp386) in serum of patients with chronic liver diseases indicate hepatic and biliary inflammationClinical Biochemistry, 2007
- Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infectionJournal of Gastroenterology and Hepatology, 2007
- Caspase activation is required for antiviral treatment response in chronic hepatitis C virus infection†Hepatology, 2006
- Apoptotic cytokeratin 18 neoepitopes in serum of patients with chronic hepatitis CJournal of Viral Hepatitis, 2005
- Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injuryHepatology, 2004
- Apoptosis and keratin intermediate filamentsCell Death & Differentiation, 2002